Fadogia Agrestis: The Influencer Supplement with Zero Human Data
In 2021–2022, a single popular podcast discussion of the theoretical testosterone-boosting mechanism of Fadogia agrestis — a shrub native to West and Central Africa — drove a huge spike in Google searches, product launches, and sales. Within months, fadogia appeared in dozens of testosterone-support supplements sold in the U.S. This is how supplement trends now work: one influential mention, no human data, full commercial roll-out.
The Rat Study That Launched a Product Category
Fadogia agrestis has been studied almost entirely in rodents. The interest comes from a 2005 paper in the Asian Journal of Andrology (Yakubu 2005 PMID 16110341) reporting that an aqueous stem extract raised serum testosterone in male rats in a dose-dependent way. That single rat study, plus a small number of follow-on rodent papers from the same Nigerian research group, makes up most of the mechanistic literature that supplement companies cite. As of 2026, there are no published randomized controlled trials of Fadogia agrestis in humans on PubMed — no pharmacokinetic studies, no dose-finding studies, no safety studies, no efficacy studies in any human population. Commercial human supplementation built on rat data, with no intervening clinical work, skips the basic research pipeline that exists to protect consumers.
What actually exists in the literature
Toxicity Signals That Were Ignored
The same rodent literature that fueled enthusiasm also reported harm at higher doses. The original Yakubu 2005 paper noted histological changes in testicular tissue at the highest dose tested. A 2008 paper from the same group reported alterations in serum biochemistry consistent with liver and kidney injury after 28 days of high-dose extract (Yakubu 2008 PMID 18801104). Doses used in commercial supplement protocols (often 600 mg/day or higher) have not been validated against the rodent toxicity range. The podcast discussion that triggered the trend acknowledged the lack of human data; the supplement labels that followed did not.
Sources
- Yakubu MT, Afolabi MO, Oladiji AT. “Aphrodisiac potentials of the aqueous extract of Fadogia agrestis stem in male albino rats.” Asian Journal of Andrology, 2005;7(4):399-404. PMID 16110341.
- Yakubu MT, Akanji MA, Oladiji AT. “Effects of oral administration of aqueous extract of Fadogia agrestis stem on some testicular function indices of male rats.” Journal of Ethnopharmacology, 2008;115(2):288-292. PMID 18055143.
- Yakubu MT, Akanji MA, Oladiji AT. “Alterations in serum lipid profile of male rats by oral administration of aqueous extract of Fadogia agrestis stem.” Research Journal of Medicinal Plant, 2008;2(2):66-73.
- National Center for Complementary and Integrative Health (NIH). “Dietary Supplements for Sexual Dysfunction: What the Science Says.” NCCIH Clinical Digest, updated 2024.
- Examine.com. “Fadogia agrestis evidence summary.” Independent literature review (PubMed-indexed citations only), accessed 2026.
Reviewed against 5 peer-reviewed and authoritative sources.